This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Rheumatoid factor

Authoring team

Rheumatoid factor or RF is an IgM autoantibody directed against the Fc portion of autologous IgG. It is present in 70% of cases of rheumatoid arthritis, and in many other autoimmune conditions.

It leads to the formation of immune complexes which activate complement with the formation of the strongly chemotactic factors C3a and C5a. It appears that, in rheumatoid arthritis, the antibody may be synthesised locally within the joints. Cell-mediated immunity may also be activated in RA. The presence of high levels of rheumatoid factor is associated with systemic complications such as vasculitis, neuropathy and nodules.

It is found in many normal members of the population, incidence increasing with age, in the absence of any pathology.

  • can be positive in the normal population (c.5% prevalence, higher in the elderly), especially at low titre (e.g. <23 units/ml)
  • will be positive in around 70% of patients with RA and >90% patients with primary Sjogren's syndrome
    • just as a normal ESR may be seen in RA, a negative rheumatoid factor does not rule RA out

Reference:

  • 1) ARC (Autumn 2012). Hands On - The approach to the patient presenting with multiple joint pain; 7(1):1-12.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.